HSV 2 vaccine - BioNTech
Alternative Names: HSV-2 - BioNTechLatest Information Update: 28 Jul 2024
Price :
$50 *
At a glance
- Originator BioNTech; University of Pennsylvania
- Class RNA vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Herpes simplex virus type 2 infections
Most Recent Events
- 28 Jul 2024 No recent reports of development identified for preclinical development in Herpes simplex virus type-2 infections(Prevention) in Germany (Parenteral)
- 28 Jul 2024 No recent reports of development identified for preclinical development in Herpes simplex virus type-2 infections(Prevention) in USA (Parenteral)
- 04 Jul 2022 HSV 2 vaccine - BioNTech is available for licensing as of 27 Jun 2022. https://www.biontech.com/int/en/home/about/collaborators.html